Please Forgive Us for Prescribing Controlled Drugs to Just About Everybody

An Apology With Context, Not a Blanket Confession

“Please forgive us” is a provocative phrase. It implies that medicine did something wrong, and in many cases, it did. Some patients received high doses, risky combinations, weak monitoring, automatic refills, or treatment plans with no clear destination. Pharmaceutical marketing, rushed appointments, fragmented care, pressure to eliminate symptoms, and limited access to therapy or physical rehabilitation all helped turn prescriptions into the easiest available answer.

But a fair apology must also recognize that clinicians were often trying to help people whom the health care system had already failed. A patient with disabling back pain may have faced a six-week wait for physical therapy. Someone experiencing panic attacks may have been unable to afford psychotherapy. A night-shift worker struggling with concentration may have needed an evaluation that could not be completed during a ten-minute appointment.

The prescription pad became a bridge over gaps in care. Unfortunately, some bridges quietly turned into permanent housing.

What Does “Controlled” Actually Mean?

In the United States, the Controlled Substances Act classifies drugs according to accepted medical use, potential for misuse, and risk of physical or psychological dependence. Medications prescribed in ordinary clinical care generally fall within Schedules II through V. Schedule II includes many opioid pain relievers and prescription stimulants, while numerous benzodiazepines are classified as Schedule IV. A lower schedule number generally indicates tighter controls and a higher recognized misuse potential.

“Controlled” does not mean “bad.” It means the medication deserves additional care. A chainsaw is controlled by a trigger and safety guard because it is useful and powerfulnot because nobody should ever cut a tree.

The safest approach is neither casual prescribing nor reflexive prohibition. It is deliberate prescribing: the right patient, the right indication, the smallest effective amount, meaningful follow-up, and an exit plan when the treatment is meant to be temporary.

How Medicine Got Onto the Refill Treadmill

Symptoms Were Easier to Measure Than Function

A pain score, anxiety rating, or concentration complaint fits neatly into a medical chart. Life is messier. Can the patient walk to the mailbox? Return to work? Sleep without falling? Attend a child’s soccer game? Cook dinner without becoming exhausted?

When success is defined only as “Does it hurt less?” a dose increase can look reasonable even when the patient is becoming sleepier, less active, more constipated, and less engaged with daily life. Modern opioid guidance encourages clinicians to establish treatment goals related to both pain and function, discuss benefits and risks, and reassess whether continued therapy is improving the patient’s life.

Fast Relief Created Long-Term Momentum

Controlled drugs often work quickly. An opioid can reduce acute postoperative pain. A benzodiazepine can calm intense anxiety. A stimulant may improve core ADHD symptoms. That immediate effect is memorable to both patient and clinician.

The problem arrives later. The original condition may change, tolerance may develop, side effects may accumulate, or the medication may become woven into the person’s physical and emotional stability. By then, asking whether it should continue can feel like reopening a contract everyone assumed had already been signed in permanent ink.

Stopping Was Harder Than Starting

Physical dependence is not the same as addiction. Dependence means the body has adapted to a drug and may produce withdrawal symptoms if the dose drops too quickly. Addiction, or substance use disorder, involves impaired control, compulsive use, craving, or continued use despite harm.

Confusing the two has injured patients in both directions. Some people with addiction were described as merely “dependent” and did not receive treatment. Other people taking medication exactly as prescribed were labeled as addicts because withdrawal appeared when therapy was interrupted.

Federal guidance warns that long-term opioids should not usually be stopped abruptly. Rapid discontinuation can cause withdrawal, uncontrolled pain, psychological distress, suicidal thoughts, or attempts to obtain opioids from unsafe sources.

Care Was Fragmented

One clinician treated pain. Another treated anxiety. A third addressed sleep. Each prescription may have looked defensible when viewed alone, while the complete medication list told a more alarming story.

Prescription drug monitoring programs help clinicians review controlled-substance dispensing histories and identify overlapping prescriptions, multiple prescribers, or unexpectedly early fills. They are valuable safety tools, although a database should begin a conversationnot replace clinical judgment or turn a patient encounter into a courtroom drama.

The Three Drug Families at the Center of the Conversation

Opioids: Powerful Relief With Serious Trade-Offs

Prescription opioids remain important for selected patients, including those with severe acute injuries, major surgery, cancer-related pain, palliative-care needs, or other situations in which expected benefits outweigh risks. They are not automatically inappropriate simply because they are controlled.

However, opioids can cause sedation, constipation, respiratory depression, tolerance, dependence, misuse, overdose, and opioid use disorder. Risks tend to increase with higher doses, longer exposure, certain medical conditions, and combinations with other sedating substances. CDC guidance states that nonopioid treatments are at least as effective as opioids for many common forms of acute pain and generally favors nonopioid approaches for chronic pain when appropriate.

Opioid dispensing has declined substantially. The national retail dispensing rate fell from 46.8 prescriptions per 100 people in 2019 to 35.4 in 2024, although major differences remain among states and counties. Lower prescribing alone does not solve pain, addiction, or overdose, but it shows that the era of nearly automatic opioid expansion has changed.

Benzodiazepines: Calm Now, Complications Later

Benzodiazepines such as alprazolam, clonazepam, diazepam, and lorazepam can be invaluable for seizures, alcohol withdrawal, procedural sedation, and carefully selected anxiety-related conditions. They can also cause drowsiness, memory problems, impaired coordination, falls, tolerance, and physical dependence.

The FDA requires boxed warnings addressing misuse, addiction, dependence, and withdrawal. Combining benzodiazepines with opioids or other central nervous system depressants can produce profound sedation and life-threatening respiratory depression.

Discontinuation must be handled with particular care. A 2025 multidisciplinary clinical guideline advises against abruptly stopping benzodiazepines in physically dependent patients. Tapers should be individualized, monitored, and adjusted according to symptoms; some people who have taken these medications for years may require a very gradual process.

Prescription Stimulants: Legitimate Treatment, Real Diversion Risk

Prescription stimulants are established treatments for ADHD and narcolepsy. For appropriately diagnosed patients, they can improve attention, impulse control, organization, and everyday functioning. The answer is not to revive the myth that every adult seeking ADHD care merely wants “study drugs.”

Still, stimulants have misuse, diversion, addiction, cardiovascular, and overdose risks. In 2023, the FDA required stronger, more consistent warnings across the prescription stimulant class. Clinicians are advised to assess misuse risk, monitor patients, discuss secure storage, and clearly explain that medication should never be shared.

A careful ADHD evaluation is therefore not an obstacle placed in front of treatment. It is part of treatment. The same is true of follow-up appointments that assess sleep, blood pressure, appetite, mood, substance use, and whether the medication is improving real-world function.

Today’s Overdose Crisis Is Not Exactly the Crisis of 2015

Prescription overuse helped shape the early opioid epidemic, but the modern overdose landscape is increasingly dominated by an unpredictable illegal drug supply. In 2023, approximately 69% of U.S. overdose deaths involved synthetic opioids other than methadone, primarily illegally manufactured fentanyl and its analogs. Polysubstance deaths involving opioids, stimulants, counterfeit pills, benzodiazepines, and other substances have become a defining feature of the crisis.

Overdose deaths declined sharply in 2024, an encouraging public health development, but tens of thousands of families still lost someone. The decline should inspire expansion of effective interventions, not a victory parade with confetti cannons and a “mission accomplished” banner.

Responsible prescribing remains important, but it is only one part of the response. Communities also need naloxone access, evidence-based addiction treatment, safer transitions from hospitals and jails, mental health services, overdose education, and practical support for housing and recovery.

For opioid use disorder, medications such as buprenorphine, methadone, and naltrexone can reduce cravings, support recovery, and prevent overdose. Treating these medications as merely “replacing one drug with another” ignores their medical purpose and discourages people from seeking lifesaving care.

What Safer Controlled-Drug Prescribing Looks Like

1. Confirm the Diagnosis

   Back pain deserves an examination. Panic symptoms deserve a mental health assessment. Concentration problems deserve an evaluation that considers sleep deprivation, depression, trauma, substance use, thyroid disease, medication effects, and ADHD rather than assuming the answer before the question is finished.

2. Define a Measurable Goal

   “Feel better” is understandable but difficult to measure. “Walk for 15 minutes,” “sleep at least six hours,” “finish work without missing deadlines,” or “reduce panic attacks from five per week to one” creates a clearer standard for deciding whether treatment works.

3. Discuss Benefits, Risks, and Duration Before the First Dose

   Patients deserve to know whether a medication is intended for three days, three months, or potentially longer. They also deserve plain-language information about sedation, driving, alcohol, pregnancy, secure storage, dependence, withdrawal, and overdose.

4. Use the Lowest Effective Dose and Reassess

   A refill should not function as a monthly ritual requiring less thought than ordering the same sandwich. Clinicians should review benefits, adverse effects, functional progress, interactions, and evidence of misuse or diversion.

5. Use Monitoring Without Humiliation

   Prescription databases, toxicology testing, pill counts, and treatment agreements may improve safety in selected situations. These measures should be explained as standard clinical tools rather than punishments reserved for patients whom the office considers suspicious.

6. Reduce Risk When Continued Treatment Is Appropriate

   This may include avoiding dangerous drug combinations, coordinating among prescribers, addressing sleep apnea or lung disease, prescribing naloxone when indicated, reviewing alcohol use, and securing medications away from children, visitors, or anyone who might take them accidentally.

7. Taper Collaboratively When Risks Outweigh Benefits

   Tapering is not simply subtraction. It may require physical therapy, nonopioid medication, cognitive behavioral therapy, sleep treatment, treatment for depression or anxiety, addiction consultation, frequent follow-up, and permission to pause when withdrawal symptoms become difficult.

Evidence-based guidelines from CDC and the Department of Veterans Affairs emphasize individualized care rather than rigid formulas. Nonpharmacologic and nonopioid treatments are generally preferred for chronic pain, but decisions about starting, continuing, reducing, or discontinuing opioids should be based on each patient’s benefits, risks, circumstances, and goals.

Repair Requires Compassion, Not Collective Punishment

Medicine’s response to overprescribing cannot be a dramatic swing from “Here is a refill forever” to “We no longer prescribe this, good luck.” That merely replaces one careless policy with another.

Some patients have taken stable doses for years, remain functional, follow treatment plans, and experience meaningful benefit. Others are struggling with severe side effects, uncontrolled symptoms, dependence, diversion, or substance use disorder. A spreadsheet cannot distinguish them. A thoughtful clinical relationship sometimes can.

Patients should not be blamed for trusting medical advice. Clinicians should not be treated as villains for every prescription written during a period when training, standards, incentives, and available evidence differed. Accountability is necessary, but shame is a poor quality-improvement strategy.

A useful apology sounds less like “We are sorry, therefore your medication disappears today” and more like this: “We should have explained the risks more clearly. We should have followed your progress more closely. We will not abandon you while we build a safer plan.”

Experiences From the Refill Treadmill: Four Composite Stories

The following scenarios are fictional composites based on common clinical patterns. They do not describe identifiable patients or claim to be firsthand personal experiences.

The Prescription That Outlived the Injury

A warehouse employee injures his back while lifting a pallet. An urgent care clinician prescribes a few days of opioid pain medication. The medication helps him sleep, but the pain continues. He receives another prescription from primary care, then another while waiting for an imaging appointment.

Six months later, the original muscle injury has healed, yet he is less active than before. He avoids movement because he fears reinjury. He is constipated, tired, and no longer playing basketball with his son. The medication lowers his pain score from seven to five, but his life has become smaller.

A productive appointment begins when his clinician stops debating whether the pain is “real.” Of course it is real. The better question is whether the current treatment is restoring his life. Together, they begin physical rehabilitation, address his fear of movement, prescribe naloxone, and create a gradual opioid reduction plan. Progress is uneven, but the patient is treated as a partner rather than a suspect.

The Anxiety Pill That Became a Morning Requirement

A woman receives a benzodiazepine during a period of intense grief. Initially, she takes it occasionally. Over several years, “as needed” quietly becomes twice daily. She does not feel intoxicated, seek early refills, or take more than prescribed. She simply wakes with shaking and panic if she misses a dose.

When a new clinician says, “You should never have been on this,” she hears an accusation. She did not prescribe it to herself. A safer conversation acknowledges that the medication may once have helped, that her body is now dependent, and that sudden discontinuation could be dangerous.

Her taper begins with small reductions, counseling, treatment for persistent anxiety, and frequent check-ins. Some months bring progress; others require holding the dose steady. Success is not measured by how quickly the prescription reaches zero. It is measured by safety, participation, and improved functioning.

The College Prescription That Traveled

A student with properly diagnosed ADHD receives a stimulant and experiences meaningful academic improvement. The trouble starts when classmates ask to borrow pills during final exams. At first, she refuses. Later, she gives one to a close friend who insists it is harmless.

Her clinician eventually asks directly about sharing, storage, and refill timing without adopting the tone of a detective in a television interrogation room. The student admits what happened. Instead of immediate dismissal, the clinician explains the risks, develops a secure storage plan, reviews the treatment agreement, and increases monitoring.

The encounter preserves legitimate ADHD treatment while addressing diversion. Safety improves because honesty does not automatically trigger abandonment.

The Patient With Three Prescribers and No Villain

An older adult receives an opioid from an orthopedic specialist, a benzodiazepine from a psychiatrist, and a sleep medication from primary care. Each clinician assumes the others are monitoring the full regimen. After a fall, a pharmacist notices the combination and contacts the care team.

No single prescription explains the entire event. The danger emerged from accumulation, poor communication, and a medication list that was technically available but functionally invisible.

The solution is not a frantic purge. The clinicians coordinate, identify which symptoms each drug targets, prioritize the most dangerous combination, involve the patient and family, and taper one medication at a time. The patient gains balance and alertness without being thrown into uncontrolled pain or withdrawal.

These experiences share a lesson: safer prescribing is rarely achieved through one heroic decision. It happens through small acts of attentionasking what the medicine is accomplishing, checking what else the patient takes, noticing when function declines, and refusing to confuse caution with cruelty.

Conclusion: Prescribe Less Automatically and Care More Deliberately

Controlled substances are neither miracle cures nor moral contaminants. They are powerful medical tools whose benefits depend on diagnosis, dosage, duration, monitoring, and context.

Medicine should apologize for periods when refills replaced reassessment, side effects were minimized, dependence was poorly explained, and fragmented care exposed patients to preventable harm. It should also apologize to people who were abruptly cut off, stigmatized, or abandoned during the effort to correct those mistakes.

The better future is not a country in which nobody receives opioids, benzodiazepines, or stimulants. It is one in which prescriptions begin with a clear purpose, continue only when benefits remain meaningful, and endwhen ending is appropriatewith preparation, patience, and support.

We may never know exactly how many prescriptions were unnecessary. We can decide that the next one will not be thoughtless.